MIG - Press Review

German Bionic debuts a new Exoskeleton with upper- and lower body assistance

„TechCrunch“ reports about a product innovation of Exoskeleton Start-up German Bionic, a MIG portfolio company.

Find out more

Europes Biotechs need a Ecosystem for Financing

Byline article of Michael Motschmann, General Partner MIG Capital AG, and Prof. Dr. Andrea Pfeifer, CEO AC Immune.

Find out more

BioNTech´s Success Offers Antidote to EU Biopharma Skittshness

Dr. Matthias Kromayer, General Partner MIG Capital AG, explains on „Bloomberg“ the impact of the success of BioNTech to European Biopharma Industry.

Find out more

The Project Biontech

The documentation „The Project Biontech“ tells the story of the development und the firm an the first Covid-19 vaccine, including statements of Michael Motschmann, General Partner MIG Capital AG.

Find out more

The unintended consequences of Vestager´s tougher take of „killer acquisitions“.

„Politico“ setzt sich mit der neuen EU-Politik zur Übernahme strategischer Start-ups auseinander, mit Zitaten von Dr. Matthias Kromayer, General Partner der MIG Capital AG.

Find out more

MIG Capital AG invests in iOMX

„Business Insider“ and other media report about MIG Capital AGs new investment in biotech firm iOMX.

Find out more

An exit needs several elementsn

Interview with Michael Motschmann, General Partner MIG Capital AG, about successful exits

Find out more

Share ownership has to be more attractive

Interview with Michael Motschmann, General Partner MIG Capital AG, respective to the new DAX40.

Find out more

BioNTech – how all started

„Wiwo.de“ tells the story of BioNTech and the role of MIG Fonds as First Investor.

Find out more

Affiris sells Parkinson Portfolio to AC Immune

Among others news agency Reuters reports about a transaction of Affiris´ Parkinson vaccine, a MIG portfolio company. The portfolio changes to the Swiss Biotech firm AC Immune.

Find out more

Find out more

Find out more

Find out more

„This will be a big thing“

Online-interview with Dr. Matthias Kromayer, General Partner MIG AG, in leading Austrian Magazine „Trend“ about the future of Biotech and the portfolio of MIG Fonds.

Find out more

Private Equity for small money

„FAZ“ is analyzing opportunities and risks of MIG Fonds.

Fiind out more

Macron demands till 2030 ten 100-Billion-Euro Start-ups

As part of a conference president Macron calls till 2030 the construction of ten European start-ups with a valuation of 100 Billion Euro. Among the participants Dr. Jan Goetz, CEO of IQM, a MIG portfolio company.

Find out more

Qutac – German Industry forms alliance in Quantum Computing

„FAZ“ reports about Qutac, a project of the German industry refering Quantum Computing. MIG portfolio company IQM is part of Qutac.

Find out more

Sun, Beach – and now Start-ups

„Wirtschaftswoche“ describes the founders scene in Mecklenburg-Vorpommern with quotes of Tobias Gebhardt, CEO GWA Hygiene GmbH, a MIG portfolio company.

Find out more

MIG: AMSilk Raises 29M Euro in Series C Funding

Several media report about the newest funding for AMSilk.

Find out more

Find out more

MIG reports best year in history

Several media report about the best year in history of MIG AG

Find out more

Find out more

Find out more

Advantage for mRNA-Vaccines

"tagesschau.de" has a look at the future of vaccinations against Covid-19 with quotes of Dr. Matthias Kromayer, General Partner MIG AG.

Mehr erfahren

How to bring buildings into a computer

„Münchner Merkur“ portrays NavVis, a MIG-portfolio company.

Biontech Investors put on Quantum Computing

„Manager Magazin Online“ reports about the assignment of Helmut Jeggle as Member of the Supervisory Board of IQM. The article mentions MIG Fonds and Michael Motschmann, Gneneral Partner of MIG AG, as first investor of the Finnish-German Start-up in Quantum Computing.

Find out more

„Investors got their money seven times back“

Interview with Michael Motschmann, General Partner of MIG AG, in „VC-Magazin“ about the investment in BioNTech

Find out more

„What in Germany is possible“ and „The Heroes of the German Vaccine Fairy Tale“

„DIE WELT“ describes the development of MIG portfolio company BioNTech und the founders. The article refers to the role of Michael Motschmann and Dr. Matthias Kromayer, General Partner of MIG AG. Additionally an interview in „DIE WELT“ with Michael Motschmann.

Find out more

Success with molecules

In an article about Biotech IPOs in the US, „Börse Online“ quotes Dr. Matthias Kromayer, General Partner MIG AG.

Find out more

Serious deficits

Angela Merkel and other heads of government claim a digital pact. Dr. Jan Goetz, CEO of MIG portfolio company IQM, calls for an European approach to Quantum Computing.

Find out more

Many ideas, little money

„tagesschau.de“ reports about investments in Biotech in Germany and quotes Michael Motschmann, General Partner MIG AG.

Find out more

The Deals of German Biotech Investors

Trade Magazin „CHEManager“ reports about German Investors in Biotech, among them MIGs investments.

Find out more

MIG Fonds expand in the French Alps

„Finanzwelt“ reports about a new investment of MIG Fonds in Zadient Technologies.

Find out more

Everything started with a dream

„Manager Magazin“ interviews Michael Motschmann, General Partner of MIG AG, and Co-Investors Thomas Strüngmann and Helmut Jeggle about their joint involvement at BioNTech SE.

Find out more

Screen Supplier to sell

„FAZ“ reports about the start of a trade sale of Cynora, a portfolio company of MIG Fonds.

FT People of the Year: BioNTech´s Ugur Sahin and Özlem Türeci

„Financial Times“ chooses BioNTech´s Ugur Sahin and Özlem Türeci as „People of the Year“. In a cover story MIG AG is described as a first investor and Matthias Kromayer, General Partner of MIG AG, is quoted.

Find out more

Bloomberg prognosis, 13. Dezember 2020, First Covid Vaccines´ Triumph Raises Hope for Cancer Fight

„Bloomberg prognosis“ explains how mRNA vaccines against Covid-19 raises hope in the fight against cancer, with quotes of Dr. Matthias Kromayer, General Partner of MIG AG.

Find out more

From Biontech to Sputnik V

Dr. Matthias Kromayer, General Partner MIG AG, explains in a byline article for „Handelsblatt“ the differencies between the vaccines against Covid-19.

Find out more

Competition for the Super-Brain

„Bayerische Staatszeitung“ explains the development of Quantum Computing and reports about IQM, a MIG portfoliocompany.

Find out more

MIG Fonds invests in Innatera

Several Media report about investment of MIG Fonds in new portfolio company Innatera

Find out more

Find out more

Find out more

The Billionaires behind the Vaccine

„FAS“ describes the engagement of BioNTech investors Andreas and Thomas Strüngmann and the role of Michael Motschmann, General Partner of MIG AG, financing the firm from Mainz.

Find out more

Founder couple from Mainz develops vaccine against corona

In a title story „Handelsblatt“ portrays the founder of BioNTech und mentions the role of Michael Motschmann, General Partner of MIG AG, as first investor

Find out more

Vaccine milestone heralds „normal life“ by next spring

The breaking news about important steps toward a vaccine against Covid-19 causes, that newspapers around the world like „The Times“ report about the founders of BioNTech, a MIG portfolio company, on their frontpages.

Find out more

The Start-up of Gloria Seibert shaped the market in an early stage

„Handelsblatt“ explains in a comprehensive article the business model of Temedica and mentions MIG Fonds as investor.

Find out more

Corona-Vaccine of BioNTech effective in over 90 percent of cases

MIG-portfolio company BioNTech und partner Pfizer are announcing important improvements of their vaccine against Covid-19. Media around the world are reporting, among them „FAZ“.

Find out more

IPolitics should stay away

In an interview with „FAZ“ Pfizer´s top executive Kathrin Jansen explains the cooperation with BioNTech, a MIG portfolio company, in the search for a vaccine against Covid-19

Find out more

The Munich Start-up factory

An article in „FAS“ describes Technische Universität München (TUM) as excellent incubator of start-ups with quotes of Dr. Axel Thierauf, Venture Partner of MIG AG, about MIG portfolio companies with origin at TUM.

We were convinced early about the IPO plans of Immatics

Interview with Dr. Matthias Kromayer, General Partner MIG AG, about the IPO of our portfolio company Immatics. .

Find out more

Quantum Advantage

In a detailed story business magazine „Capital“ presents start-up IQM from Finland, a MIG portfolio company, as a leading european firm in the sector of Quantum Computing.

Comeback of Plastics

The magazine „SPIEGEL“ points out the USP of MIG portfolio company APK in the recycling of plastics.

Biotech-Firm Immatics from Tübingen with Nasdaq Listing

„Handelsblatt.com“ reports about the Listing of MIG-portfolio company Immatics at New Yorks Nasdaq.

Find out more

Singapurs Funds Temasek invests in BioNTech

„Manager Magazin“ reports about a 250 million investment of Temasek in BioNTech, a MIG portfolio company.

Find out more

The next quantum leap

In an article in detail „Focus“ describes the state of the art of quantum computing in Europe and mentions MIG portfolio company IQM as a main player.

10 promising European deeptech startups leading us into the future

Platform „EU-Startups“ provides an overview of European „deeptech startups“ and highlights MIG-portfolio company IQM and the founder Dr. Jan Goetz.

Find out more

The start-up of this German build hardware for Quantumcomputers

„Gründerszene“ portrays Dr. Jan Goetz, CEO of IQM, a MIG portfolio company.

Find out more

Biontech and Pfizer are planning to produce millions of units of Corona-vaccine this year

Handelsblatt.com reports about the plans of BioNTech, a portfolio company of MIG Fonds, to develop and produce a vaccine against Covid-19 together with Pfizer.

Find out more

Saving the World

Weekly Magazine „DIE ZEIT“ reports about pharmaceutical companies searching for vaccines against SARS CoV-2 focusing on BioNTech, a MIG portfolio company.

Find out more

Ugur Sahin : the immunologist racing to find a vaccine

„Financial Times“ portrays Prof. Dr. Ugur Sahin, CEO of MIG portfolio company BioNTech, who started the race to find the first vaccine against SARS CoV-2.

Find out more

BioNTech in China alliance with Fosun over coronavirus vaccine candidate

Newswire „Reuters“ reports about a cooperation of BioNTech, a MIG portfolio company. Together with Fosun Pharmaceutical a vaccine against Covid-19 should be developed first in China.

Find out more

Find out more

Find out more

Pfizer weighs working with BioNTech on potential coronavirus vaccine

Reuters reports, that Pfizer weighs working with MIG portfolio company BioNTech on a potential coronavirus vaccine.

Find out more

Cynora introduces fluorescent blue emitter

Trade magazine „OLED-Brief“ reports about the first commercial OLED-product of Cynora, a MIG portfolio company.

Find out more

„We align our portfolio along trends of the future“

„Finanzwelt“ reports about the year 2019 of MIG AG.

Find out more

Advancecor achieves good data of Revacept

Trade magazine „transkript“ reports about a successful phase-II-study of biontech-firm AdvanceCOR, a MIG portfolio company.

Find out more

IQM CEO: Europe could lead the quantum computing revolution.

„Venturebeat“ interviews Dr. Jan Goetz, CEO of MIG portfolio company IQM. Dr. Goetz explains, how Europe could lead the quantum computing industry.

Find out more

People of the Year

„Frankfurter Allgemeine Zeitung“ calls Ugur Sahin, CEO of BioNTech, a MIG portfolio company, to the people of the year 2019.

Find out more

Injection of hope

Leading scientific magazine „Nature“ shows in an article the example of a cancer patient, who achieves with individual RNA-based vaccine from BioNTech, a MIG portfolio company, striking results.

Find out more

Konux starts international projects

The platform „Munich Startup“ describes how MIG portfolio company Konux internationalizes the business.

Find out more

Biontech aquires less money as expected

German newspaper „FAZ“ reports about the IPO of Biontech at Nasdaq. The valuation of the MIG portfolio company was 3.4 Billion US Dollar

Find out more

Bill and Melinda Gates invest in German biotech firm BioNTech

"Handelsblatt" reports about a 50 million Euro donation of Gates foundation to BioNTech to develop vaccines against HIV and tuberculosis. BioNTech is a MIG portfolio company.

Find out more

GWA Hygiene acquires HyHelp

The founders platform of „Wirtschaftswoche“ reports about the acquisition of Hyhelp by MIG portfolio company GWA Hygiene.

Find out more

BioNTech: Company from Mainz collects 325 Millionen Dollar

Several media report a financing round of BioNTech, a MIG portfolio company, of 325 Millionen Dollar, one of the largest single financing rounds of a private owned european biotech firm ever.

Find out more

Find out more

An Oil Firm turns to a Plastic Disposal Company

„Handelsblatt“ describes the transformation of MOL, the largest private owned company in Ungary, which fosters strongly the business of plastic disposal in cooperation with APK, a MIG portfolio company.

Find out more

„We achieved some highlights in 2018“

„Finanzwelt“ reports about MIG AGs fiscal year 2018.

Find out more

Protection against Hospital Germs

An online-magazine of Kreditanstalt für Wiederaufbau (KfW) describes the business model of GWA, a MIG portfolio company.

Find out more

About Spiders

German newspaper „Süddeutsche Zeitung“ reports about the different kinds of spiders and spider webs. Because the demand of silk is constantly increasing, the article although describes the activities of MIG-portfolio company Amsilk, which produces artificial silk.

Find out more

Affiris collects 10 Mio. EUR in financing round

A trade magazine informs about a financing round of MIG portfolio company Affiris, Vienna, in which MIG Fonds are participating.

Find out more

Alibabas surprising investment in Konux

„Gründerszene“ informs about Alibabas investment in Konux, a MIG portfolio company.

Find out more

German Start-up presents bracelet from artifcial spider silk

„Handelsblatt“ reports about a product innovation of Amsilk, a MIG portfolio company.

Find out more

Success in Venture Capital Business

Michael Motschmann, General Partner of MIG AG, explains the German landscape of financing start-ups.

Find out more

Top 10 IoT Companies rocking your socks off

Platform „Enterprise Management 360 Grad“ elaborates a ranking of most innovative IoT firms, which names beside of Hitachi, Verizon and Huawei although Konux and NavVis, both MIG portfolio companies.

Find out more

The third Life

„Handelsblatt“ reports about the onboarding of Volker Kefer, a ex Member of Board of Deutsche Bahn, at Konux, a MIG portfolio company.

Find out more

Infineon buys Start-up from Dresden for 124 Mill. Euro

„Handelsblatt.com“ reports about the recent exit of MIG Fonds.

Find out more

Frontrunner of personalized medicine

Newspaper „FAZ“ portrays BioNTech as pionier of a new medicine against cancer. MIG Fonds are named as one of the first investors.

We create the companies of the next decades

Michael Motschmann, General Partner MIG AG, and Dr. Helmut Jeggle, MD Athos Service GmbH (Family Office Strüngmann) explain in a common interview the future of German biotechnology.

Find out more

Biotechfirma Immatics will mit Krebstherapien zum Einhorn werden

„Handelsblatt.com“ reports about the progress of Immatics, a MIG portfolio company, with cancer therapy and describes possible IPO plans.

Find out more

Millions for the fight against flu

The regional Rhein-Main edition of „FAZ“ reports about new developments of BioNTech, a MIG portfolio company

Mehr erfahren

GWA Hygiene, 2,5 million Euro for digital inspection

„Wirtschaftwoche Online“ reports about the entry of MIG Fonds with start-up GWA Hygiene

Find out more

Millions for GWA Hygiene

„Handelsblatt“ covers the financing round of start-up GWA Hygiene with participation of MIG-Fonds.

Immatics convinces Genmab with own antibodies

Trade magazine „transcript“ reports about the cooperation between Immatics, a MIG portfolio company, with Europes biggest biotech-enterprise.

Find out more

Konux receives cogX Award

MIG portfolio company Konux receives in London prestigious cogX Award..

Find out more

We introduce robotic to construction sites

Kewazo, a new MIG portfolio company, presents in the „elevator pitch“ of „Wirtschaftswoche“ its business model.

Find out more

Just gotta save the world real quick

„Mitteldeutsche Zeitung“ explains the new disruptive method of APK, a MIG-Portfolio company, recycling packaging waste into synthetic material.

Find out more

MIG Fonds secure financing of clinical surveys

„Finanzwelt“ reports about a financing round of MIG with several Co-Investors of 6 Millionen Euro to Biotech Start-up advancedCOR.

Find out more

MIG Fonds invest in new Start.up

„Finanzwelt“ and „VC Magazin“ report about the new investment of MIG in start-up KEWAZO.

Find out more

Find out more

Interview with Michael Motschmann

In a discussion with „Venture Capital Magazin“ Michael Motschmann, General Partner of MIG AG, point out the relevance of a performing capital market for young companies.

Find out more

Wallpainting as heater

The regional newspaper „Nordbayerischer Kurier“ describes the business model of FutureCarbon, a portfolio company of MIG Fonds.

Find out more

On the road to routine diagnostics

The trade magazine „transkript“ portrays in detail Biocrates, a portfolio company of MIG Fonds, and highlights the extraordinary potential of this start-up.

MIG AG continues course for success

Report about the fiscal year 2017 of MIG AG

Find out more

The most exiting innovations in Germany

In an interview with „WELT“ Prof. Dr. Joachim Henkel, chair owner for innovation research of TU Munich, designates Konux and Navvis, two portfolio companies of MIG Fonds, as outstanding start-ups.

Find out more

Europe´s biggest private biotech company raises $270 million

The news agency „Reuters“ reports about funding of $270 million by BioNTech, a portfolio company of MIG Fonds.

Find out more

More space for the fight against cancer

A regional edition (Rhein-Main) of „Frankfurter Allgemeine Zeitung“ describes the work and progresses of Biontech, a portfolio company of MIG Fonds.

Find out more

Growth Engine Venture Capital

Michael Motschmann, Member of the Board and Venture Partner of MIG AG, explains in a byline article, why Venture Capital is so important for the future of the German economy.

Vaccination against Cancer

The article explains the progress in the fight against cancer and spotlights the success of BioNTech, a portfolio company of MIG Fonds.

Find out more

Will this scientist find the magic bullet versus cancer?

„Focus“ about the progress on individualized cancer immunotherapy with spot on the work of Ugur Sahin, CEO of BioNTech, a portfolio company of MIG Fonds.

Cobwebs can improve breast implants

„Die Welt“ about technological progress at AmSilk, a portfolio company of MIG Fonds

Find out more

A cool madness

„Frankfurter Allgemeine Zeitung“ about the invention of the founders of Efficient Energy, a portfolio company of MIG Fonds.

MIG Fonds distribute ca. 90 Mio. EUR

„Finanzwelt“ takes up a press release of MIG AG, that MIG Fonds in the first half-year 2017 invested ca. 25 Mio. EUR in 16 portfolio companies and distributed ca. 64 Mio EUR to private investors.

Find out more

To vaccinate against cancer

„Handelsblatt“ informs about the recent advances of BioNTech to fight cancer and mention MIG Fonds as investors.

Find out more

Fresh colours for displays

A detailed article in „Handelsblatt“ comments on the business model of Cynora and mentions IPO-plans of the management for 2019 in USA. MIG Fonds are emntioned as investors.

Find out more

Here Start-ups get more than just a cash injection

The trade journal „Bilanz“ presents the 20 main venture capitalists in Germany, among them Michael Motschmann, general partner of MIG AG.

Find out more

„A shoe made of silk“

„Frankfurter Allgemeine Sonntagszeitung“ illustrates the innovative technology of AmSilk, a portfolio company of MIG Fonds, and its application in textile industry. It is also reported about the chance how the synthetic silk done by AMSilk could resurrect the german textile industry.

Find out more

America‘s Favourite

„Handelsblatt“ with a portrait of Konux

Find out more

"Deutschlands 100 klügste Köpfe" (Germany’s 100 masterminds)

„Handelsblatt“ has awarded „Deutschlands 100 klügste Köpfe“. Holger Sedlak (Efficient Energy), Georg Schroth (Navvis) und Prof. Dr. Ugur Sahin (Biontech) belong to these 100 innovators. We proudly congratulate the founders of our portfolio companies on this success.

Find out more

Like silk

In a detailed article Süddeutsche Zeitung presents technology and business model of AMSilk GmbH (portfolio company of MIG Fonds)

Find out more

MIG Fonds cash in on Brain

Börsen Zeitung talks about MIG Fonds and Brain AG – involvement and exit in progress

Find out more

“Investment company MIG awakens stock exchange fantasies”

In a discussion with the Frankfurter Allgemeine Zeitung, Michael Motschmann, General Partner and member of the Executive Board at MIG AG, explains what plans the VC investors of MIG Verwaltungs AG have in store.

Funds for founders

Michael Motschmann, General Partner and member of the Executive Board at MIG AG, is quoted several times in an article by the Süddeutsche Zeitung on the funding options for start-up companies.

Digital prize "The Spark" – More guts will do you good

Handelsblatt and McKinsey have awarded Konus and NaVvis, two portfolio companies of MIG Fonds, with the digital prize “The Spark” for innovations in industry 4.0.

Find out more

Efficient Energy - cool stuff

Handelsblatt presents Efficient Energy, a MIG portfolio company, and describes their new refrigeration technology as an innovative breakthrough. MIG Fonds are named as venture capitalists.

Find out more

Genentech lays $310M wager on BioNTech’s mRNA cancer vaccine platform

The trade journal FierceBiotech outlines the newest deal involving the payment of 310 million USD to MIG portfolio company BioNTech from Roche’s affiliated company Genentech.

Find out more

Interview with Michael Motschmann and Dr. Matthias Kromayer

The two MIG AG Executive Board members comment to recent successful exits, flotation of MIG portfolio company BRAIN and their next strategical moves with Venture Capital Magazin.

The dream team of the biotech industry

Frankfurter Allgemeine Sonntagszeitung presents Özlem Türeci and Ugur Sahin, CEOs of Ganymed and BioNTech respectively. Both companies belong to the MIG portfolio.

Billionaire-backed Ganymed grabs ASCO spotlight

The renowned trade journal FierceBiotech reports on ASCO, the largest oncology congress in the world. MIG portfolio company Ganymed is one of the stars of the show with their new phase 2b trial.

Find out more

Off through the museum with a ‘data hoover’

FAZ has published a detailed article discussing how the 3D trolley developed by NavVis, an MIG portfolio company, captures and maps interior spaces.

Find out more

An addition to the MIG Fonds portfolio

Finanzwelt talks about MIG Fonds‘ acquisition of a 16.26 % share in Konux Inc in a series A round, making Konux the youngest company in MIG’s portfolio.

Find out more

Cancer vaccines

Handelsblatt presents Biontech as an inspiring start-up business in the biotech sector in a full-page profile, making several references to MIG Fonds as the participating VC investor.

A new Germany

NavVis, an MIG portfolio company, took pride of place as one of the hidden champions in an article listing over 50 successful digital business models.

Find out more

Brain risks IPO despite the storm raging on the stock market

The response to being given the go-ahead for an IPO was obviously so good that the biotech firm Brain wants to follow through with its first steps onto the capital market despite the storm that’s currently raging.

Jury awards top-class prize to NavVis

This year, the internationally renowned DLD prize “Digital Star” goes to NavVis, an MIG Fonds portfolio company. The start-up company from Munich won the main prize entitled “Innovation of the Year”.